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Patients with chronic kidney disease (CKD) have markedly
higher rates of severe vitamin D deﬁciency and reduced
ability to convert 25-(OH)vitamin D into the active form,
1,25-dihydroxyvitamin D [1]. In the setting of CKD, sec-
ondary hyperparathyroidism develops as a consequence
of reduced renal production of active vitamin D and phos-
phate retention resulting in hypocalcaemia and hyperpho-
sphataemia. This is a process that is dangerously linked
with metabolic bone disease, arterial calciﬁcations and
cardiovascular mortality [2]. Therefore, the conventional
rationale for vitamin D treatment in CKD is to slow the pro-
gression of secondary hyperparathyroidism.
In addition to the classical pathway for activation of
25-(OH)vitamin D to 1,25-(OH)2 vitamin D, a peripheral
autocrine pathway exists and results in calcitriol synthe-
sis in a variety of peripheral extra-renal tissues [3]. By
binding with its intracellular vitamin D receptor (VDR) in
these tissues, calcitriol can regulate cellular proliferation
and differentiation, inﬂammation, the immune system
and the endocrine system, including insulin resistance,
lipid metabolism and renin–angiotensin system (RAS) [4].
Interestingly, active vitamin D analogues have shown
demonstrably favourable effects on proteinuria, likely
through interference with RAS [5, 6]. The discovery of
this non-classical pathway has brought new signiﬁcance
to the importance of addressing nutritional vitamin D
deﬁciency [7].
Vitamin D deﬁciency has been associated with all-cause
and cardiovascular mortality in patients with CKD,
whereas therapies with vitamin D and analogues have
been associated with reduced mortality, recently also in
meta-analysis of observational studies (Table 1). However,
evidence from randomized controlled trials (RCTs) sup-
porting a survival beneﬁt from active and/or pre-active
vitamin D administration in CKD patients is still lacking.
Moreover, it is not even known whether different types of
active vitamin D, selective or non-selective VDR activators,
or precursors have a diversiﬁed effect on mortality in the
CKD population.
In the present issue of the Clinical Kidney Journal, Mann
et al. [8] present a meta-analysis of RCTs to investigate
the effect of oral vitamin D therapy versus placebo on
mortality and cardiovascular outcomes among adults
with CKD, whereas vitamin D supplementation was not
found to exert any signiﬁcant effect on these hard out-
comes. Analysis of pooled data displayed a substantial
overlap in conﬁdence intervals and homogeneity between
study results. Stratiﬁcation of trials by CKD stage, weekly
vitamin D dose, proportion of diabetic subjects and
vitamin D compound displayed similar results. In detail,
13 trials that, overall, enrolled 1469 patients with CKD
stage 1–5D were selected for analysis and none of them
had mortality as a primary outcome. These studies were
mainly designed to test biochemical or bone histological
end points and consequently had a rather short follow-up.
On the whole 41 all-cause deaths (2.8%) were recorded
during a follow-up ranging from 3 to 104 weeks (mean
41 weeks). Of note, about two-thirds of the patients
(n = 1087) had been followed for <1 year (mean 21, range
3–48 weeks), registering 17 all-cause deaths (41%), 8 car-
diovascular deaths (62%) and 18 cardiovascular events
(86%). Only two trials (total patient number = 233) had a
follow-up time up to 2 years, but they registered only 11
deaths of which, 5 had a cardiovascular cause. Taken
together, these observations could indicate that the dur-
ation of follow-up may have been insufﬁcient to capture
possible differences in mortality, as correctly stated from
the authors in the limitation section and as well as sug-
gested by the relatively low number of events displayed.
Moreover, not negligible differences are also present in
patient populations (End Stage Renal Disease in 5 of 13
trials) and in interventions, above all considering the hetero-
geneity in administered vitamin D compounds and dosages.
In conclusion, it is not the time to say that interventions
based on vitamin D may reduce mortality in patients with
CKD, but the opposite cannot be said yet beyond all rea-
sonable doubt. In fact, given the paucity of good quality
data, the reliability of the pooled results is still uncertain.
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Table 1. Systematic literature reviews on vitamin D in patients with CKD
First author,
year Methodology Number of trials/patients pooled in the analysis Outcomes tested Main results
Palmer, 2007
[9]
Meta-
analysis
76 studies/3667 CKD patients Biochemical markers of mineral metabolism, CVand mortality
outcomes
Vitamin D compounds did not reduce the risk for death, bone
pain, vascular calciﬁcation or parathyroidectomy
Haiyang, 2009
[10]
Meta-
analysis
6 RCTs/174 CKD patients with sHPT Suppression of circulating PTH and serum ALP No signiﬁcant differences between intermittent intravenous
and oral calcitriol in the treatment of secondary
hyperparathyroidism for efﬁcacy
Palmer, 2009
[11]
Meta-
analysis
60 studies/2773 CKD RD patients Clinical, biochemical and bone outcomes Vitamin D compounds lowered serum PTH at the expense of
increasing serum calcium and phosphorus
Palmer, 2009
[12]
Meta-
analysis
16 studies/894 CKD NRD patients Biochemical, bone, CV, and mortality outcomes Vitamin D compounds lowered serum PTH at the expense of
increasing serum calcium and phosphorus
Geary, 2010
[13]
Meta-
analysis
15 RCTs/369 children with CKD stages 2–5D Clinical, biochemical and bone outcomes Vitamin D therapy signiﬁcantly reduced PTH levels without
consistent differences between routes of administration,
frequencies of dosing or vitamin D preparations
Wang, 2010
[14]
Meta-
analysis
17 studies (8 RCTs and 9 observational studies,
among which 5 were prospective studies of CKD
RD patients)/315 860 patients
CV disease outcomes The ﬁve studies of patients who received dialysis showed
consistent reductions in CVmortality in those who received
vitamin D supplements
Kandula, 2011
[15]
Meta-
analysis
22 studies (17 observational and 5 RCTs)/1593
patients with CKD NRD, CKD RD and renal
transplant recipients
Biochemical outcomes Vitamin D supplementation (ergocalciferol or cholecalciferol)
appears to improve 25(OH)D and 1,25(OH)2D levels while
reducing PTH levels without increasing the risk for
hypercalcaemia and hyperphosphataemia
Pilz, 2011 [16] Meta-
analysis
10 prospective studies/6853 patients with CKD Mortality Higher 25(OH)D circulating levels are associated with
signiﬁcantly improved survival
Cheng, 2012 [6] Meta-
analysis
9 RCTs/832 patients with stage 2–5 CKD Clinical and biochemical outcomes Paricalcitol suppresses iPTH and lowers proteinuria without
an increased risk of adverse events
Duranton, 2013
[17]
Meta-
analysis
14 observational studies/194 932 patients with
CKD NRD and CKD RD
Mortality Therapies with 1,25-dihydroxyvitamin D and analogues are
associated with reduced mortality in CKD patients
Han, 2013 [18] Meta-
analysis
9 RCTs/1113 patients with CKD NRD Clinical and biochemical outcomes Paricalcitol is effective in lowering PTH in CKD patients and is
also effective in lowering proteinuria in diabetic CKD patients
with a trend towards hypercalcaemia
Xu, 2013 [19] Meta-
analysis
18 RCTs/1836 patients with CKD at stage 3–5 Reduction in proteinuria, renal function and risk of death Vitamin D therapy lowered proteinuria without any negative
inﬂuence on renal function. No superiority for newer versus
established vitamin D analogues. No differences regarding
the risk of death
de Borst, 2013
[20]
Meta-
analysis
6 RCTs/688 patients with proteinuria (84% treated
with ACEi or ARB)
Reduction in proteinuria Paricalcitol and calcitriol both reduced proteinuria
Zheng, 2013
[21]
Meta-
analysis
20 observational studies/491 857 CKD patients
(CKD RD in 17 of 20 studies)
All-cause and CVmortality Participants receiving vitamin D had lower all-cause and CV
mortality. Patients receiving paricalcitol had a survival
advantage over those that received calcitriol
Theodoratou,
2014 [22]
Umbrella
review
107 systematic literature reviews, 74 meta-
analyses of observational studies of plasma
vitamin D concentrations and 87 meta-analyses
of RCTs of vitamin D supplementation
Limited to CKD (RCTs/participants): bone pain (4/109), bone
fractures (4/181 RD), mortality (4/477 NRD; 5/233 RD), PTX (2/
133 RD), hypercalcaemia (7/612 NRD; 5/182 RD),
hyperphosphataemia (2/245 NRD; 2/59 RD), risk of requiring
dialysis (4/301 NRD)
A clear role of vitamin D does not exist for any outcome,
except for hypercalcaemia in CKD NRD
RCT, randomized clinical trial; CKD, chronic kidney disease; CV, cardiovascular; sHPT, secondary hyperparathyroidism; PTH, parathyroid hormone; ALP, alkaline phosphatase; RD, requiring dialysis; NRD, not requiring
dialysis; ACEi, angiotensin-converting enzyme inhibitor.
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